The primary goal of ulcerative colitis (UC) treatment is to induce and maintain remission with few to no clinical symptoms remaining. Conventional therapies (e.g., 5-ASAs, corticosteroids) are typically used to treat mild to moderate patients, whereas IV and subcutaneous TNF-α inhibitors are primarily reserved for moderate to severe patients refractory to conventional treatment or for first-line treatment in the most severe patients. Lack of primary response or loss of response to TNF-α inhibitors is an ongoing concern; however, the IV-delivered CAM inhibitor Entyvio (Takeda) is a recent entry to the treatment armamentarium that offers an alternative mechanism of action for these patients, and has led to increasing competition among the biologics.
- What patient share do key therapies and brands garner by line of therapy in newly diagnosed UC patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed UC patients?
- How has Entyvio been integrated into the treatment algorithm?
- What proportion of UC patients receive drug therapy within 365 days of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within 365 days of diagnosis?
- What percentage of UC patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?
- What are the product-level compliance and persistency rates among drug-treated patients with UC?
Treatment Algorithms: Claims Data Analysis provides detailed analysis of brand usage across different lines of therapy using real-world data patient-level claims data so you can accurately assess your source of business and quantify areas of opportunity for increasing your brand share.